Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HEXCEL CORP /DE/HXL · Entity 3705 | President EMEA/AP & Industrial | February 02, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HEXCEL CORP /DE/
Report date February 02, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,736 |
Reported balance
After 2026-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-02 · Grant · Acquired 1,736 · Balance 1,736 F1: Each restricted stock unit ("RSU") represents a conditional right to receive one share of common stock of the issuer. F2: The RSUs vest as to two-thirds on the second anniversary of the date of grant, and the remaining one-third on the third anniversary of the date of grant, and convert into an equivalent number of shares of common stock of the issuer. |
| Non-Qualified Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $81.59 · Expires 2036-02-02 | Direct | 4,175 |
Reported balance
After 2026-02-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-02-02 · Grant · Acquired 4,175 · Balance 4,175 F3: The non-qualified stock options vest in equal increments on the first three anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a conditional right to receive one share of common stock of the issuer.
F2: The RSUs vest as to two-thirds on the second anniversary of the date of grant, and the remaining one-third on the third anniversary of the date of grant, and convert into an equivalent number of shares of common stock of the issuer.
F3: The non-qualified stock options vest in equal increments on the first three anniversaries of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 02, 2026 Filed Feb 3, 2026 23:16 UTC | HEXCEL CORP /DE/ HXL · Entity 3705 | GrantNon-Qualified Stock Options · Derivative | 4,175 | $0.00 Strike: $81.59 | $0.00 |
DisclosureSEC source: 0001193125-26-036064 · ownership.xml · derivative · entry 2 Brayle Lilian Regis · CIK 0002089052 · President EMEA/AP & Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,175 Underlying: Common Stock · 4,175 shares Expires 2036-02-02 F3 · derivative.exercise_date: The non-qualified stock options vest in equal increments on the first three anniversaries of the grant date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 23:16 UTC | HEXCEL CORP /DE/ HXL · Entity 3705 | GrantRestricted Stock Units · Derivative | 1,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-036064 · ownership.xml · derivative · entry 1 Brayle Lilian Regis · CIK 0002089052 · President EMEA/AP & Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,736 Underlying: Common Stock · 1,736 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a conditional right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The RSUs vest as to two-thirds on the second anniversary of the date of grant, and the remaining one-third on the third anniversary of the date of grant, and convert into an equivalent number of shares of common stock of the issuer. F2 · derivative.expiration_date: The RSUs vest as to two-thirds on the second anniversary of the date of grant, and the remaining one-third on the third anniversary of the date of grant, and convert into an equivalent number of shares of common stock of the issuer. Read SEC document |
| October 27, 2025 Filed Oct 29, 2025 20:23 UTC | HEXCEL CORP /DE/ HXL · Entity 3705 | GrantRestricted Stock Units · Derivative | 11,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-256381 · ownership.xml · derivative · entry 1 Brayle Lilian Regis · CIK 0002089052 · President EMEA/AP & Industrial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,683 Underlying: Common Stock · 11,683 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a conditional right to receive one share of common stock of the issuer. F2 · derivative.exercise_date: The RSUs vest as to two-fifths on the second anniversary of the date of grant, and one-fifth on the third, fourth and fifth anniversaries of the date of grant, and convert into an equivalent number of shares of common stock of the issuer. F2 · derivative.expiration_date: The RSUs vest as to two-fifths on the second anniversary of the date of grant, and one-fifth on the third, fourth and fifth anniversaries of the date of grant, and convert into an equivalent number of shares of common stock of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.